LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Ouvert

13.42 -1.03

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.22

Max

13.63

Chiffres clés
By Trading Economics
Revenu	-23M -14M
Ventes	-22M 72M
Marge bénéficiaire	-18.944
Employés	624
EBITDA	-23M -6.4M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+43.43% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-491M 2.3B
Ouverture précédente	14.45
Clôture précédente	13.42

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

8.81 / 10.18 Support & Résistance

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mai 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Résultats

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Résultats

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Acquisitions, Fusions, Rachats

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Résultats

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Résultats

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Résultats

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Résultats

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Résultats

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Actions en Tendance

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Résultats

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

43.43% hausse

Prévisions sur 12 Mois

Moyen 19.42 USD 43.43%

Haut 22 USD

Bas 13.54 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

8.81 / 10.18Support & Résistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.